Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Peter Neumeister
Immunohistochemical Double Hit Score Enhances NCCN-IPI and Is Associated With Detrimental Outcomes in Refractory or Relapsing Patients With Diffuse Large B Cell Lymphoma
British Journal of Haematology
Hematology
Ensuring Center Quality, Proper Patient Selection and Fair Access to Chimeric Antigen Receptor T-Cell Therapy: Position Statement of the Austrian CAR-T Cell Network
Memo - Magazine of European Medical Oncology
Oncology
Hematology
Related publications
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
The Double Hit Signature Identifies Double-Hit Diffuse Large B-Cell Lymphoma With Genetic Events Cryptic to FISH
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
Prophylaxis With High-Dose Methotrexate Significantly Reduces CNS Dissemination in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) and High-Risk CNS-IPI Score
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
BioMed Research International
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Diffuse Large B-Cell Lymphoma With Combined TP53 Mutation and MIR34A Methylation: Another &Ldquo;double Hit” Lymphoma With Very Poor Outcome?
Oncotarget
Oncology
Short Diagnosis-To-Treatment Interval Is Associated With High Risk and Poor Outcomes in Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
R-Chop With or Without Bevacizumab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma: Final MAIN Study Outcomes
Haematologica
Hematology
C-Reactive Protein-To-Albumin Ratio Is an Independent Poor Prognosis and Improving NCCN-Ipi Score in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Clinical Analysis of 414 Cases
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
